11,342 Shares in Guardant Health, Inc. (NASDAQ:GH) Bought by Cibc World Markets Corp

Cibc World Markets Corp acquired a new position in shares of Guardant Health, Inc. (NASDAQ:GH) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 11,342 shares of the company’s stock, valued at approximately $346,000.

Several other institutional investors and hedge funds also recently modified their holdings of GH. R Squared Ltd acquired a new stake in Guardant Health during the 4th quarter valued at $26,000. SBI Securities Co. Ltd. purchased a new position in Guardant Health in the 4th quarter valued at about $43,000. Jones Financial Companies Lllp lifted its stake in shares of Guardant Health by 43.5% in the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company’s stock worth $82,000 after acquiring an additional 817 shares in the last quarter. Van ECK Associates Corp lifted its stake in shares of Guardant Health by 47.4% in the fourth quarter. Van ECK Associates Corp now owns 2,887 shares of the company’s stock worth $88,000 after acquiring an additional 929 shares in the last quarter. Finally, KBC Group NV lifted its stake in shares of Guardant Health by 63.6% in the fourth quarter. KBC Group NV now owns 5,658 shares of the company’s stock worth $173,000 after acquiring an additional 2,200 shares in the last quarter. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on GH. Stifel Nicolaus lifted their price objective on Guardant Health from $45.00 to $53.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Morgan Stanley upped their price target on shares of Guardant Health from $42.00 to $52.00 and gave the company an “overweight” rating in a report on Thursday, March 6th. The Goldman Sachs Group raised their price objective on shares of Guardant Health from $49.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Piper Sandler increased their price target on shares of Guardant Health from $34.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Guggenheim reiterated a “buy” rating and issued a $56.00 price target on shares of Guardant Health in a research note on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating, According to MarketBeat, Guardant Health has a consensus rating of “Buy” and an average price target of $48.40.

Guardant Health Trading Up 1.4 %

NASDAQ GH opened at $46.74 on Tuesday. The company has a 50-day moving average price of $44.02 and a two-hundred day moving average price of $33.79. Guardant Health, Inc. has a 52 week low of $15.81 and a 52 week high of $50.89. The stock has a market cap of $5.77 billion, a price-to-earnings ratio of -13.13 and a beta of 1.50.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.15). The business had revenue of $201.81 million during the quarter, compared to the consensus estimate of $192.50 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. As a group, equities research analysts expect that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.